Hypoxic pulmonary hypertension(HPH) is a syndrome characterized by the increase of pulmonary vascular tone and the structural remodeling of peripheral pulmonary arteries.The aim of specific therapies for hypoxic pulmo...Hypoxic pulmonary hypertension(HPH) is a syndrome characterized by the increase of pulmonary vascular tone and the structural remodeling of peripheral pulmonary arteries.The aim of specific therapies for hypoxic pulmonary hypertension is to reduce pulmonary vascular resistance,reverse pulmonary vascular remodeling,and thereby improving right ventricular function.Iptakalim,a lipophilic para-amino compound with a low molecular weight,has been demonstrated to be a new selective ATP-sensitive potassium(K ATP) channel opener via pharmacological,electrophysiological,biochemical studies,and receptor binding tests.In hypoxia-induced animal models,iptakalim decreases the elevated mean pressure in pulmonary arteries,and attenuates remodeling in the right ventricle,pulmonary arteries and airways.Furthermore,iptakalim has selective antihypertensive effects,selective vasorelaxation effects on smaller arteries,and protective effects on endothelial cells,but no effects on the central nervous,respiratory,digestive or endocrine systems at therapeutic dose.Our previous studies demonstrated that iptakalim inhibited the effects of endothelin-1,reduced the intracellular calcium concentration and inhibited the proliferation of pulmonary artery smooth muscle cells.Since iptakalim has been shown safe and effective in both experimental animal models and phase I clinical trials,it can be a potential candidate of HPH in the future.展开更多
Cumulative evidence suggests that renal vascular endothelial injury play an important role in initiating and extending tubular epithelial injury and contribute to the development of ischemic acute renal failure.Our pr...Cumulative evidence suggests that renal vascular endothelial injury play an important role in initiating and extending tubular epithelial injury and contribute to the development of ischemic acute renal failure.Our previous studies have demonstrated that iptakalim's endothelium protection is related to activation of SUR2B/Kir6.1 subtype of ATP sensitive potassium channel(K ATP) in the endothelium.It has been reported that SUR2B/Kir6.1 channels are widely distributed in the tubular epithelium,glomerular mesangium,and the endothelium and the smooth muscle of blood vessels.Herein,we hypothesized that activating renal K ATP channels with iptakalim might have directly neroprotective effects.In this study,glomerular endothelial,mesangial and tubular epithelial cells which are the main cell types to form nephron were exposed to oleic acid(OA) at various concentrations for 24 h.0.25 μl/ml OA could cause cellular damage of glomerular endothelium and mesangium,while 1.25μl/ml OA could lead to the injury of three types of renal cells.It was observed that pretreatment with iptakalim at concentrations of 0.1,1,10 or 100 μmol/L prevented cellular damage of glomerular endothelium and tubular epithelium,whereas iptakalim from 1 to 100 μmol/L prevented the injury of mesangial cells.Our data showed iptakalim significantly increased survived cell rates in a concentration-dependent manner,significantly antagonized by glibenclamide,a K ATP blocker.Iptakalim played a protective role in the main cell types of kidney,which was consistent with natakalim,a highly selective SUR2B/Kir6.1 channel opener.Iptakalim exerted protective effects through activating SUR2B/Kir6.1 channels,suggesting a new strategy for renal injury by its endothelial and renal cell protection.展开更多
该文以降压靶标膜ATP敏感钾通道(ATP-sensitive potassium channel,KATP)为研究对象,构建其基于配体和基于受体结构的药效团模型,并分别筛选中药化学成分数据库(traditional Chinese medicine database,TCMD),利用分子对接评价筛选结果...该文以降压靶标膜ATP敏感钾通道(ATP-sensitive potassium channel,KATP)为研究对象,构建其基于配体和基于受体结构的药效团模型,并分别筛选中药化学成分数据库(traditional Chinese medicine database,TCMD),利用分子对接评价筛选结果,发现具有潜在KATP开放作用的中药降压活性成分。其中,基于配体的药效团模型(ligand based pharmacophore,LBP)以对人源KATP具有开放活性的48个化合物为研究对象,利用Hypogen模块进行构建,最优模型由1个氢键受体、1个氢键供体、1个疏水基团、1个芳香环和5个排除体积组成,预测训练集化合物活性相关系数为0.876 4,测试集相关系数为0.705 8,辨识有效性指数N为3.304,综合评价指数CAI为2.616;以KATP同源模建模型(PM0079770)为研究对象,构建基于受体的药效团模型(structure-based pharmacophore,SBP),最优模型具有6个氢键受体、8个氢键供体、7个疏水基团和18个排除体积,辨识有效性指数N为2.200,综合评价指数CAI为2.017。分别用2个最优模型对TCMD数据库进行筛选,对候选化合物进行Lipinski五规则及ADMET性质预测研究,LBP模型命中171个化合物,SBP模型命中178个化合物。利用分子对接技术分别对上述2组潜在中药活性成分进行评价,按照打分值由大到小的排序,分别选取对接pose个数的前3%为潜在活性化合物。得到由LBP模型虚拟筛选得到的10个化合物、由SBP模型虚拟筛选得到的2个化合物,共12个具有潜在KATP开放活性的中药成分。该研究为发现新的KATP开放剂提供了思路。展开更多
基金supported by National Major Scientific and Technological Special Project for"Significant New Drugs Development"(2011ZX09302-003-02)
文摘Hypoxic pulmonary hypertension(HPH) is a syndrome characterized by the increase of pulmonary vascular tone and the structural remodeling of peripheral pulmonary arteries.The aim of specific therapies for hypoxic pulmonary hypertension is to reduce pulmonary vascular resistance,reverse pulmonary vascular remodeling,and thereby improving right ventricular function.Iptakalim,a lipophilic para-amino compound with a low molecular weight,has been demonstrated to be a new selective ATP-sensitive potassium(K ATP) channel opener via pharmacological,electrophysiological,biochemical studies,and receptor binding tests.In hypoxia-induced animal models,iptakalim decreases the elevated mean pressure in pulmonary arteries,and attenuates remodeling in the right ventricle,pulmonary arteries and airways.Furthermore,iptakalim has selective antihypertensive effects,selective vasorelaxation effects on smaller arteries,and protective effects on endothelial cells,but no effects on the central nervous,respiratory,digestive or endocrine systems at therapeutic dose.Our previous studies demonstrated that iptakalim inhibited the effects of endothelin-1,reduced the intracellular calcium concentration and inhibited the proliferation of pulmonary artery smooth muscle cells.Since iptakalim has been shown safe and effective in both experimental animal models and phase I clinical trials,it can be a potential candidate of HPH in the future.
基金supported by grants from National New Drug Research and Development of Key Project(2010ZX09401-307,2008ZX09101-006,2008ZXJ09004-018 and 2009ZX09301-002)
文摘Cumulative evidence suggests that renal vascular endothelial injury play an important role in initiating and extending tubular epithelial injury and contribute to the development of ischemic acute renal failure.Our previous studies have demonstrated that iptakalim's endothelium protection is related to activation of SUR2B/Kir6.1 subtype of ATP sensitive potassium channel(K ATP) in the endothelium.It has been reported that SUR2B/Kir6.1 channels are widely distributed in the tubular epithelium,glomerular mesangium,and the endothelium and the smooth muscle of blood vessels.Herein,we hypothesized that activating renal K ATP channels with iptakalim might have directly neroprotective effects.In this study,glomerular endothelial,mesangial and tubular epithelial cells which are the main cell types to form nephron were exposed to oleic acid(OA) at various concentrations for 24 h.0.25 μl/ml OA could cause cellular damage of glomerular endothelium and mesangium,while 1.25μl/ml OA could lead to the injury of three types of renal cells.It was observed that pretreatment with iptakalim at concentrations of 0.1,1,10 or 100 μmol/L prevented cellular damage of glomerular endothelium and tubular epithelium,whereas iptakalim from 1 to 100 μmol/L prevented the injury of mesangial cells.Our data showed iptakalim significantly increased survived cell rates in a concentration-dependent manner,significantly antagonized by glibenclamide,a K ATP blocker.Iptakalim played a protective role in the main cell types of kidney,which was consistent with natakalim,a highly selective SUR2B/Kir6.1 channel opener.Iptakalim exerted protective effects through activating SUR2B/Kir6.1 channels,suggesting a new strategy for renal injury by its endothelial and renal cell protection.
文摘该文以降压靶标膜ATP敏感钾通道(ATP-sensitive potassium channel,KATP)为研究对象,构建其基于配体和基于受体结构的药效团模型,并分别筛选中药化学成分数据库(traditional Chinese medicine database,TCMD),利用分子对接评价筛选结果,发现具有潜在KATP开放作用的中药降压活性成分。其中,基于配体的药效团模型(ligand based pharmacophore,LBP)以对人源KATP具有开放活性的48个化合物为研究对象,利用Hypogen模块进行构建,最优模型由1个氢键受体、1个氢键供体、1个疏水基团、1个芳香环和5个排除体积组成,预测训练集化合物活性相关系数为0.876 4,测试集相关系数为0.705 8,辨识有效性指数N为3.304,综合评价指数CAI为2.616;以KATP同源模建模型(PM0079770)为研究对象,构建基于受体的药效团模型(structure-based pharmacophore,SBP),最优模型具有6个氢键受体、8个氢键供体、7个疏水基团和18个排除体积,辨识有效性指数N为2.200,综合评价指数CAI为2.017。分别用2个最优模型对TCMD数据库进行筛选,对候选化合物进行Lipinski五规则及ADMET性质预测研究,LBP模型命中171个化合物,SBP模型命中178个化合物。利用分子对接技术分别对上述2组潜在中药活性成分进行评价,按照打分值由大到小的排序,分别选取对接pose个数的前3%为潜在活性化合物。得到由LBP模型虚拟筛选得到的10个化合物、由SBP模型虚拟筛选得到的2个化合物,共12个具有潜在KATP开放活性的中药成分。该研究为发现新的KATP开放剂提供了思路。
